Page 3 - Virtual Scientific Program News Today : Breaking Ne

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy

Published: June 4, 2021

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy

Source: investegate.co.uk

Novartis Pharma AG: Novartis announces Tabrecta first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC

Published: June 4, 2021

Tabrecta (capmatinib) showed a median overall survival (OS) of 20.8 months in treatment-naïve patients and 13.6 months in previously-treated patients in first published mature data1,2 Tabrecta achieved

Source: finanznachrichten.de

Daiichi Sankyo Company, Limited: Patritumab Deruxtecan Data at ASCO Demonstrates Tumor Response Across Multiple Resistance Mechanisms in Patients with Advanced EGFR-Mutated NSCLC

Published: June 4, 2021

Oral presentation highlighting extended follow-up data from phase 1 study in patients with locally advanced or metastatic TKI-resistant, EGFR-mutated NSCLC shows promising clinical activity Data

Source: finanznachrichten.de

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis announces Tabrecta® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC

Published: June 4, 2021

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis announces Tabrecta® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC

Source: investegate.co.uk

Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy

Published: June 4, 2021

/PRNewswire/ -- Novartis announced today results from the pivotal Phase III RATIONALE 302 trial showing the investigational anti-PD-1 immune checkpoint...

Source: prnewswire.com

Page 3 - Virtual Scientific Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Top News In Virtual Scientific Program Today - Breaking & Trending Today

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy

Novartis Pharma AG: Novartis announces Tabrecta first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC

Daiichi Sankyo Company, Limited: Patritumab Deruxtecan Data at ASCO Demonstrates Tumor Response Across Multiple Resistance Mechanisms in Patients with Advanced EGFR-Mutated NSCLC

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis announces Tabrecta® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC

Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy

Page 3 - Virtual Scientific Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Top News In Virtual Scientific Program Today - Breaking & Trending Today

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy

Novartis Pharma AG: Novartis announces Tabrecta first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC

Daiichi Sankyo Company, Limited: Patritumab Deruxtecan Data at ASCO Demonstrates Tumor Response Across Multiple Resistance Mechanisms in Patients with Advanced EGFR-Mutated NSCLC

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis announces Tabrecta&#xAE; first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC

Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis announces Tabrecta® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC